RATIONALE: Lung fibroblasts are key mediators of fibrosis resulting in accumulation of excessive interstitial collagen and extracellular matrix, but their origins are not well defined. OBJECTIVES: We aimed to elucidate the contribution of lung epithelium-derived fibroblasts via epithelial-mesenchymal transition (EMT) in the intratracheal bleomycin model. METHODS: Primary type II alveolar epithelial cells were cultured from Immortomice and exposed to transforming growth factor-beta(1) and epidermal growth factor. Cell fate reporter mice that permanently mark cells of lung epithelial lineage with beta-galactosidase were developed to study EMT, and bone marrow chimeras expressing green fluorescent protein under the control of the fibroblast-associated S100A4 promoter were generated to examine bone marrow-derived fibroblasts. Mice were given intratracheal bleomycin (0.08 unit). Immunostaining was performed for S100A4, beta-galactosidase, green fluorescent protein, and alpha-smooth muscle actin. MEASUREMENTS AND MAIN RESULTS: In vitro, primary type II alveolar epithelial cells undergo phenotypic changes of EMT when exposed to transforming growth factor-beta(1) and epidermal growth factor with loss of prosurfactant protein C and E-cadherin and gain of S100A4 and type I procollagen. In vivo, using cell fate reporter mice, approximately one-third of S100A4-positive fibroblasts were derived from lung epithelium 2 weeks after bleomycin administration. From bone marrow chimera studies, one-fifth of S100A4-positive fibroblasts were derived from bone marrow at this same time point. Myofibroblasts rarely derived from EMT or bone marrow progenitors. CONCLUSIONS: Both EMT and bone marrow progenitors contribute to S100A4-positive fibroblasts in bleomycin-induced lung fibrosis. However, neither origin is a principal contributor to lung myofibroblasts.
RATIONALE: Lung fibroblasts are key mediators of fibrosis resulting in accumulation of excessive interstitial collagen and extracellular matrix, but their origins are not well defined. OBJECTIVES: We aimed to elucidate the contribution of lung epithelium-derived fibroblasts via epithelial-mesenchymal transition (EMT) in the intratracheal bleomycin model. METHODS: Primary type II alveolar epithelial cells were cultured from Immortomice and exposed to transforming growth factor-beta(1) and epidermal growth factor. Cell fate reporter mice that permanently mark cells of lung epithelial lineage with beta-galactosidase were developed to study EMT, and bone marrow chimeras expressing green fluorescent protein under the control of the fibroblast-associated S100A4 promoter were generated to examine bone marrow-derived fibroblasts. Mice were given intratracheal bleomycin (0.08 unit). Immunostaining was performed for S100A4, beta-galactosidase, green fluorescent protein, and alpha-smooth muscle actin. MEASUREMENTS AND MAIN RESULTS: In vitro, primary type II alveolar epithelial cells undergo phenotypic changes of EMT when exposed to transforming growth factor-beta(1) and epidermal growth factor with loss of prosurfactant protein C and E-cadherin and gain of S100A4 and type I procollagen. In vivo, using cell fate reporter mice, approximately one-third of S100A4-positive fibroblasts were derived from lung epithelium 2 weeks after bleomycin administration. From bone marrow chimera studies, one-fifth of S100A4-positive fibroblasts were derived from bone marrow at this same time point. Myofibroblasts rarely derived from EMT or bone marrow progenitors. CONCLUSIONS: Both EMT and bone marrow progenitors contribute to S100A4-positive fibroblasts in bleomycin-induced lung fibrosis. However, neither origin is a principal contributor to lung myofibroblasts.
Authors: M Brett Everhart; Wei Han; Kelly S Parman; Vasiliy V Polosukhin; Heng Zeng; Ruxana T Sadikot; Bo Li; Fiona E Yull; John W Christman; Timothy S Blackwell Journal: J Leukoc Biol Date: 2004-11-24 Impact factor: 4.962
Authors: András Masszi; Lingzhi Fan; László Rosivall; Christopher A McCulloch; Ori D Rotstein; István Mucsi; András Kapus Journal: Am J Pathol Date: 2004-12 Impact factor: 4.307
Authors: Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman Journal: J Clin Invest Date: 2014-11-03 Impact factor: 14.808
Authors: Zachary Van Rheen; Cheryl Fattman; Shannon Domarski; Susan Majka; Dwight Klemm; Kurt R Stenmark; Eva Nozik-Grayck Journal: Am J Respir Cell Mol Biol Date: 2010-06-10 Impact factor: 6.914
Authors: J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain Journal: Br J Pharmacol Date: 2010-08 Impact factor: 8.739
Authors: Chaoqun Huang; Xiao Xiao; Ye Yang; Amorite Mishra; Yurong Liang; Xiangming Zeng; Xiaoyun Yang; Dao Xu; Michael R Blackburn; Craig A Henke; Lin Liu Journal: J Biol Chem Date: 2017-07-18 Impact factor: 5.157